About
Immunotherapies
Areas of Focus
Categories
Small Molecule PharmaceuticalSouthwestern U.S.
Team (17)
Charles Schweizer, PhD
Senior Vice President, Clinical Development
ImmunoGenesis
executive
Christine Gagliardi, PhD
Senior Director, Research and Development
ImmunoGenesis
team_member
Clifford Stocks, MBA
Board Member
ImmunoGenesis
team_member
David S. Hong, MD
ImmunoGenesis
team_member
Federica Pericle, PhD, MBA
Chief Scientific Officer
ImmunoGenesis
executive
Federica “Freddi” O’Brien, BA, CPA (inactive)
Strategic Finance Consultant; Chief Financial Officer
ImmunoGenesis
executive
Clinical Trials (9)
View allTotal Trials
9
As Lead Sponsor
8
As Collaborator
1
Total Enrollment
1,520
By Phase
PHASE2: 4PHASE1/PHASE2: 2PHASE1: 2PHASE3: 1
By Status
TERMINATED: 3COMPLETED: 3RECRUITING: 2NOT_YET_RECRUITING: 1
Clinical Trials Pipeline9 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
Today
Hover over trial bars to see details
Recent Trials
NCT06836726Collaborator
Clinical Trial to Test Efficacy of Targeting Hypoxia Combined With ARSI After First-line ARSI Therapy for Castrate Resistant Prostate Cancer
PHASE2Not yet recruiting
35 participants
Started: Apr 1, 2025 · Completed: Apr 1, 2029
NCT06782555Lead Sponsor
A Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab
PHASE1/PHASE2Recruiting
71 participants
Started: Jan 8, 2025 · Completed: Jan 31, 2028
NCT06014502Lead Sponsor
Study to Evaluate IMGS-001 Treatment in Patients With Relapsed or Refractory Advanced Solid Tumors
PHASE1Recruiting
105 participants
Started: Sep 7, 2023 · Completed: Dec 31, 2027
NCT02093962Lead Sponsor
Study of TH-302 or Placebo in Combination With Pemetrexed in Patients With Non-squamous Non-small Cell Lung Cancer
PHASE2Terminated
265 participants
Started: Jun 30, 2014 · Completed: May 31, 2016
NCT02047500Lead Sponsor
Phase I TH-302 Plus Gemcitabine Plus Nab-Paclitaxel in Pancreatic Cancer
PHASE1Terminated
19 participants
Started: Jan 31, 2014 · Completed: May 31, 2016
Locations (1)
Headquarters
Houston, TX, United States
Map
Loading map...